45 related articles for article (PubMed ID: 21091088)
21. [Correlation study of expression levels of prostate-specific membrane antigen and prostate-specific antigen with Gleason score of prostate carcinoma].
Ren JQ; Chen ZQ; Zheng L; Chen Q; Li H; Zhu HG
Zhonghua Zhong Liu Za Zhi; 2004 Dec; 26(12):735-8. PubMed ID: 15733392
[TBL] [Abstract][Full Text] [Related]
22. Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.
Kristiansen I; Stephan C; Jung K; Dietel M; Rieger A; Tolkach Y; Kristiansen G
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28555048
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.
Kurek R; Nunez G; Tselis N; Konrad L; Martin T; Roeddiger S; Aumüller G; Zamboglou N; Lin DW; Tunn UW; Renneberg H
Clin Cancer Res; 2004 Sep; 10(17):5808-14. PubMed ID: 15355910
[TBL] [Abstract][Full Text] [Related]
24. Cellular distribution and heterogeneity of Psa and Psma expression in normal, hyperplasia and human prostate cancer.
Ben Jemaa A; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Horchani A; Oueslati R
Tunis Med; 2013 Jul; 91(7):458-63. PubMed ID: 24008878
[TBL] [Abstract][Full Text] [Related]
25. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
26. GAD1 is a biomarker for benign and malignant prostatic tissue.
Jaraj SJ; Augsten M; Häggarth L; Wester K; Pontén F; Ostman A; Egevad L
Scand J Urol Nephrol; 2011 Feb; 45(1):39-45. PubMed ID: 21091088
[TBL] [Abstract][Full Text] [Related]
27. Detection of extraprostatic prostate cells utilizing reverse transcription-polymerase chain reaction.
Su SL; Boynton AL; Holmes EH; Elgamal AA; Murphy GP
Semin Surg Oncol; 2000; 18(1):17-28. PubMed ID: 10617893
[TBL] [Abstract][Full Text] [Related]
28. Monoclonal antibodies and prostate-specific membrane antigen.
Chang SS
Curr Opin Investig Drugs; 2004 Jun; 5(6):611-5. PubMed ID: 15242249
[TBL] [Abstract][Full Text] [Related]
29. Prostate-specific membrane antigen: current and future utility.
Gregorakis AK; Holmes EH; Murphy GP
Semin Urol Oncol; 1998 Feb; 16(1):2-12. PubMed ID: 9508077
[TBL] [Abstract][Full Text] [Related]
30. Current use of PSMA-PET in prostate cancer management.
Maurer T; Eiber M; Schwaiger M; Gschwend JE
Nat Rev Urol; 2016 Apr; 13(4):226-35. PubMed ID: 26902337
[TBL] [Abstract][Full Text] [Related]
31. Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.
Kratochwil C; Afshar-Oromieh A; Kopka K; Haberkorn U; Giesel FL
Semin Nucl Med; 2016 Sep; 46(5):405-18. PubMed ID: 27553466
[TBL] [Abstract][Full Text] [Related]
32. Insight into the heterogeneity of prostate cancer through PSA-PSMA prostate clones: mechanisms and consequences.
Ben Jemaa A; Bouraoui Y; Oueslati R
Histol Histopathol; 2014 Oct; 29(10):1263-80. PubMed ID: 24788382
[TBL] [Abstract][Full Text] [Related]
33. [New biomarkers in prostate cancer].
Gao W; Teng LH
Zhonghua Bing Li Xue Za Zhi; 2013 Jul; 42(7):487-90. PubMed ID: 24246875
[No Abstract] [Full Text] [Related]
34. [Significance of current bio- and molecular-markers in urological cancers].
Shimazui T; Akaza H
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1008-14. PubMed ID: 15272577
[TBL] [Abstract][Full Text] [Related]
35. Prognostic markers in localized prostate cancer: from microscopes to molecules.
Harding MA; Theodorescu D
Cancer Metastasis Rev; 1998-1999; 17(4):429-37. PubMed ID: 10453287
[TBL] [Abstract][Full Text] [Related]
36. Applicability of biomarkers in the early diagnosis of prostate cancer.
Hessels D; Verhaegh GW; Schalken JA; Witjes JA
Expert Rev Mol Diagn; 2004 Jul; 4(4):513-26. PubMed ID: 15225099
[TBL] [Abstract][Full Text] [Related]
37. Peptide growth factors as biomarkers of prostate cancer risk.
Gann PH; Chatterton RT; Lee C
Epidemiol Rev; 2001; 23(1):67-71. PubMed ID: 11588856
[No Abstract] [Full Text] [Related]
38. [Tumor markers].
Fiebiger W; Wiltschke C
Acta Med Austriaca; 2001; 28(2):33-7. PubMed ID: 11382139
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
